Video

Patient-Reported Outcomes Improve with Combination Treatment for Some Patients With Hepatocellular Carcinoma

The combination treatment of Tecentriq (atezolizumab) and Avastain (bevacizumab) improved patient-reported outcomes and quality of life in a recent phase 3 study.

When compared to Nexavar (sorafenib) as a first-line treatment for patients with unresectable hepatocellular carcinoma (HCC), the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) produced better patient-reported outcomes in the recent phase 3 IMbrave150 trial, according to Dr. Peter Galle.

Galle, an oncologist at the Mainz University Medical Center in Germany, presented updated findings at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium that not only showed an improved overall survival for patients on Tecentriq and Avastain, but also a better quality of life.

Galle sat down with CURE and discussed these patient-reported outcomes, their implications for future treatment, and why patient feedback is a vital part of any study.

TRANSCRIPTION

The data was consistent throughout the different scales assessed. And there was also an exploratory analysis specific for hepatocellular carcinoma patients assessing their symptoms. And all these symptoms were also delayed compared to sorafenib. They included fatigue, jaundice, pain and others.

The implication (of this research) is that we now have not only a treatment which is efficacious and is working in patients, but also well tolerated. This is a nice addition to efficacy that patients do not suffer too much from therapy. I think it's increasingly accepted that patient reported outcomes are relevant. Whatever you do to a patient, you need to hear the patient voice, in order to learn whether the impact on the tumor is not coming at too high a price.

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Daniel Jernazian, who beat cancer twice, credits his sports mindset for survival and calls it winning his ‘life World Championship’.
Patients in rural or underserved areas may have worse outcomes, highlighting the need for early support to address care access barriers.
Image of man with text.
Dr. Emre Yekedüz discusses how ASCO 2025 highlights precision medicine, biomarkers and the gut microbiome as keys to advancing kidney cancer care.
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Mark Daniels, 83, credits CAR T-cell therapy and compassionate care for helping him overcome lymphoma and endure the isolating treatment toll.
An early study of BGB-16673 for hard-to-treat leukemia found that side effects were manageable with no new safety concerns.
Image of woman with text.
Image of goy, and text.
Watch oncology dietitian Kenisha Parikh prepare creamy lentil soup, a soothing, protein-packed recipe to help ease side effects during treatment.
Related Content